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Formoterol via Turbuhaler1 gave better protection
than terbutaline against repeated exercise challenge
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We aimed to compare the protective eect of single doses of 4?5 and 9 mg of formoterol fumarate (F), 0?5 mg
terbutaline sulphate (T) and placebo (P), all via Turbuhaler1, against exercise-induced bronchoconstriction (EIB)
in children.
Twenty-seven asthmatic children, showing a fall of 20% in FEV1 after a standardized exercise challenge test
(ECT) combined with cold air (7108C) inhalation, were randomized in this cross-over, double-blind study. They
had a mean age of 12?6 years (range 8–17 years), mean baseline FEV1 90% (73?9–105?6%) of predicted normal
value. Seventeen children used inhaled glucocorticosteroids (120–750 mg day71). ECTs were performed 15 min and
4, 8, and 12 h after drug administration.
F significantly reduced the fall in FEV1 after ECT to 5?4% (15 min), 5?2% (4 h), 8?2% (8 h) and 9?3% (12 h) after
4?5 mg, and 2?5%, 3?0%, 5?0% and 5?4% after 9 mg, compared with a fall of 18?4%, 15?7%, 15?6% and 16?5% in
FEV1 after P. The fall after T was 3?3%, 11?6%, 14?4% and 19?1% after 15 min, 4, 8 and 12 h respectively. The
dierence between F and T was statistically significant from 4 h and onward (P-value for all comparisons50?05).
Children using a single dose of either formoterol Turbuhaler 4?5 or 9 mg had significantly better
bronchoprotection against repeated exercise challenge up to 12 h compared with placebo and from 4 h onward
compared with terbutaline Turbuhaler1 0?5 mg.
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Strenuous physical activity is often associated with
symptoms of airway obstruction in children suering from
asthma. In some children exercise is the only trigger,
whereas in others it is one of several stimuli which trigger
symptoms (1). In clinical investigations, exercise tests
resulted in bronchoconstriction in more than 70% of
asthmatic children (2–4). Exercise-induced bronchocon-
striction (EIB) is thought to be elicited by airway cooling
(5) and respiratory water loss (6), which causes a change in
osmolality of the pericilliary fluid lining the respiratory
tract (7). Cold air in combination with exercise, which
represents a commonly encountered stimulus during the
daily life of many asthmatic individuals, especially in
winter, markedly worsened EIB in children with asthma (8).Received 2 December 1999 and accepted in revised form 4 January
2000.
Correspondence should be addressed to: Dr S. Soliman, AstraZe-
neca R&D Lund, S-221 87 Lund, Sweden.
0954-6111/00/070661+07 $35?00/0Short-acting inhaled b2-agonists, when taken before
exercise, have been shown to reduce/prevent EIB in most
patients (9,10). According to current international guide-
lines for treatment of asthma (11), they are the drugs of
choice for the prevention and treatment of EIB. However,
the benefit of these drugs is limited by their short duration
of protection (1). When treating children with asthma, one
has to take into account their special needs and lifestyle, for
example participation in organized school sporting and
other spontaneous physical activity during the day.
Uncontrolled symptoms limit participation in such activ-
ities and may impair self-esteem (12) and quality of life
(13,14).
Oxis1 Turbuhaler1 combines the pharmacodynamic
advantage of formoterol, such as rapid onset and long
duration of action (15,16) with the user convenience and
higher lung deposition of Turbuhaler1 (17). In a 3-month
ecacy and safety study in children, formoterol was shown
to be significantly superior to placebo in improving
morning peak expiratory flow (PEF) (18). When compared
with terbutaline 0?5 mg b.i.d. in two 3-month studies in# 2000 HARCOURT PUBLISHERS LTD
662 T. A. GRO¨NNERO¨D ET AL.adults, formoterol Turbuhaler at both 4?5 and 9 mg b.i.d.
was statistically significantly better in the control of asthma
(19,20). Concerning the protection against EIB in children,
a single dose of formoterol (metered dose) 12 mg via
pressurized metered dose inhaler gave a significantly
prolonged protection compared with salbutamol 200 mg;
the protection persisted for 12 h (21). Similar outcomes
were seen in adults in a study comparing 9mg formoterol
Turbuhaler and 0?5mg terbutaline Turbuhaler (22).
This study compared the bronchoprotection of single
doses of formoterol Turbuhaler at delivered doses of
4?5mg and 9 mg with that of 0?5mg terbutaline Turbuhaler
and of placebo, against repeated exercise challenge com-
bined with cold air in children during a period of 12 h.
Patients and methods
PATIENTS
Patients with asthma, as defined by the ATS (23), stratified
into two age groups; 6–12 and 13–17 years were enrolled.
To be included, they should have a baseline FEV1 of 80%
of predicted normal value (24) and had to show a fall of
20% in FEV1 following a standardized exercise challenge
test (ECT).
DESIGN
This was a randomized, double-blind, placebo-controlled,
cross-over study performed at two centres: one in Norway
and one in Germany. The study consisted of five visits
comprising one screening and four 12-h study days (visits
2–5), separated by washout periods of at least 72 h.
On study days, the patients inhaled 4?5 or 9mg
formoterol fumarate dehydrate (hereafter formoterol),
0?5mg terbutaline sulphate (hereafter terbutaline) or
placebo, all via Turbuhaler, in a randomized order.FIG. 1. Spirometry tests during study days.Spirometry
Schedule of spirometry test during study days is presented
in Fig. 1. Two FEV1 determinations (separated by 15 min)
were performed before study drug administration. The
mean of the two was used as baseline FEV1 and had to be
80% of predicted normal value at visits 1–5. The variation
in baseline FEV1 at visits 2–5 had to be within 20% of the
mean baseline FEV1 value at visit 1.
FEV1 was measured before, immediately after, and 5, 10
and 20 min after ECT. If FEV1 was lower after 20 min than
after 10 min, measurements continued every 10 min until
the maximum fall was observed.
Exercise challenge test (ECT)
ECTs were performed 15 min and 4, 8 and 12 h after drug
administration. The ECT at visit 1 was carried out to
determine if the patient responded to exercise with a decline
in FEV1 of at least 20% of his/her baseline value. The
patients performed a continuous running test on a treadmill
(25) with a workload adjusted to produce a maximum pulse
(approximately 180 beats min71). During exercise the
patients inhaled cold dry air (7108C) generated by the
Turboaire1 challenger through compressed medical air
with a pressure of 6 bar, through a mouthpiece. The
duration of the test varied between 4 and 8 min, depending
on the time required to reach a maximum pulse. The
individual workload established at enrolment for each
patient was maintained throughout the study. Pulse was
measured before, during and immediately after the running
period.
Before each ECT, the investigator had to judge whether it
was possible and safe for the patient to perform the ECT. If
not, the patient has to rest until the next scheduled ECT. To
exclude a possible late phase reaction, PEF was measured
at the clinic and then at home at 4, 8 and 12 h after the ECT
at visit 1.
PROTECTION BY FORMOTEROL VIA TURBUHALER1 AGAINST EIB 663Patients discontinued any concomitant use of broncho-
dilators 6–72 h prior to visits, depending on the duration of
drug action. Anti-histamines and disodium cromoglycate
were discontinued 48 and 24 h, respectively, prior to visits.
Inhaled and nasal glucocorticosteroids (GCSs) were
allowed, provided that they were used at constant doses
30 days prior to visit 1 and throughout the study.
Pharmacodynamic parameters
AUC0–20: The area under the time–eect curve in the
interval 0–20 min was computed using the
trapezoidal rule.
AUC0–12 h: The area under the time–eect curve in the
interval 0–12 h.
Ebase: The mean of the two FEV1 measurements at
the beginning of each study day (before study
drug at visits 2–5).
Epre: FEV1 just before each ECT.
Emin: The minimum post-exercise value measured.
Eav: The average eect based on Epre within the
study day, i.e. AUC0–12 h/12.
IndexEIB: The bronchial response to exercise was ex-
pressed as maximum fall in FEV1 from the pre-
exercise value (the % fall index):
IndexEIB  Epre ÿ Emin
Epre
 100
AverageEIB: The mean post-exercise lung function relative
to the FEV1 value measured just before each ECT (Epre):
AverageEIB  AUC0ÿ20
20 Epre
Safety
Information about adverse events was obtained by means
of an open standardized question to the patient at the clinic
visits: ‘Have you/your child had any health problems since
the previous visit/questioning?’.
Statistics
In a previous study in children, the within patient coecient
of variation in the lowest post-exercise vs. pre-exercise
FEV1 ratio was 13%. With similar variation in this study, a
sample size of 24 evaluable patients would give a
probability of 80% to detect an eect of 11%. This
assumed a two-sided test on a 5% significance level.
IndexEIB was compared between treatments with an
additive analysis of variance (ANOVA) model with factors
patient, visit and treatment. 95% confidence intervals were
constructed for the pair-wise treatment comparisons. The
values from each exercise test within a study day were
treated in separate analyses. The duration of the protective
eect was evaluated by comparing the active treatments
with placebo at 15 min and then for as long as the dierence
was statistically significant.Possible dierences in treatment eects between the two
age groups (6–12 and 13–17 years) were investigated using a
separate ANOVA model.
Ethics
Independent Ethics Committees in Norway and Germany
approved the study. Signed informed consent was obtained
from the parent and from the patient if he/she was older
than 12 years or oral consent if the child was younger than
12 years, prior to enrolment in the study.
Results
Twenty-seven patients (15 males and 12 females) were
randomized into the study. Their mean age was 12?6 years
(range 8–17 years), mean weight 47 kg (25–71 kg) and mean
height 154 cm (135–180 cm). All but two were Caucasians.
Thirteen children belonged to the younger age group (6–12
years) and 14 to the older age group (13–17 years). The
mean baseline FEV1 (Ebase) at visit 1 was 2?56 l (1?66–4?15 l)
corresponding to 90% of predicted normal value (74–
106%). The mean percentage fall in FEV1 after exercise at
enrolment (IndexEIB) was 32% (19?7–49?5%). The distribu-
tion of some patient characteristics at entry is shown in
Fig. 2.
Seventeen patients were on regular treatment with
inhaled GCSs (120–750 mg) and four patients were using
a long-acting b2-agonist (salmeterol) on a regular basis.
Eight patients used anti-histamines; one patient used
inhaled disodium cromoglycate, one patient used nasal
disodium cromoglycate and two patients used nasal GCSs.
FEV1 BEFORE ECT
Mean baseline FEV1 measured before drug administration
(Ebase) was about the same for all treatments; 2?50 l
(placebo), 2?56 l (formoterol 4?5 mg), 2?55 l (formoterol
9mg) and 2?52 l (terbutaline 0?5mg). Both doses of
formoterol as well as terbutaline gave statistically signifi-
cantly higher FEV1 values than placebo, 15min after
administration (Table 1). No statistically significant dier-
ence was seen between the 4?5 and 9 mg dose of formoterol
(Fig. 3).
Concerning a 12 h average of pre-exercise FEV1 (Eav),
both formoterol doses gave significantly higher bronchodi-
lating eects than both placebo and terbutaline.
PROTECTION AGAINST EIB
Both formoterol doses gave a significantly higher degree of
protection against EIB than placebo, between 15 min and
12 h after study drug administration. Compared with
terbutaline, both formoterol doses gave a significantly
better protection at 4, 8 and 12 h after drug administration.
Fifteen minutes after drug administration, terbutaline gave
a significantly better protection than placebo. The eect
FIG. 2. Distribution of patient characteristics at entry.
TABLE 1. Analyses of pre-exercise FEV1 measured 15 min after drug administration
Epre; 15 min (l) Eav (l)
Contrast Est. 95% CI P-value Est. 95% CI P-value
Placebo 2?53 2?47 2?59 2?58 2?54 2?62
Formoterol 4?5 mg 2?69 2?62 2?75 2?69 2?65 2?73
Formoterol 9 mg 2?70 2?64 2?76 2?70 2?66 2?74
Terbutaline 0?5 mg 2?66 2?60 2?72 2?63 2?59 2?67
Formoterol 9 mg/Placebo 106?7 103?3 110?2 50?001 104?5 102?2 106?8 50?001
Formoterol 4?5 mg/Placebo 106?0 102?5 109?7 50?001 104?1 101?8 106?6 50?001
Terbutaline 0?5 mg/Placebo 104?9 101?6 108?3 0?004 101?7 99?5 104?0 0?12
Formoterol 9mg/Terbutaline 0?5 mg 101?7 98?5 105?0 0?29 102?7 100?5 105?0 0?02
Formoterol 4?5 mg/Terbutaline 0?5 mg 101?1 97?8 104?5 0?51 102?4 100?1 104?7 0?04
Formoterol 9 mg/Formoterol 4?5 mg 100?6 97?4 103?9 0?70 100?3 98?1 102?6 0?78
Pre-exercise FEV1, Epre; average value, Eav.
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test performed 4 h after administration (Fig. 4). The mean
fall in FEV1 after placebo during the randomized study
days was 18?4% at the 15-min test, which was less than the
mean fall measured at the screening visit (32?0%). The
results of the statistical analyses are given in Table 2. No
major dierences were seen between the age groups
concerning the treatment eects (Fig. 5). Statistical tests
comparing treatments were not made due to the limited
number of patients in each subgroup.SAFETY
There were no adverse events of clinical relevance or
considered causally related to treatment.
Discussion
The current guidelines (11) recommend the use of short-
acting b2-agonists for prevention and treatment of acute
FIG. 3. Mean Epre at dierent time points after
administration of study drugs, presented as changes from
baseline (%). Placebo (*), formoterol 4?5 mg (&),
formoterol 9 mg (D), terbutaline 0?5 mg ().
FIG. 4. IndexEIB at dierent time points after drug
administration. Placebo (*), formoterol 4?5 mg (&),
formoterol 9 mg (D), terbutaline 0?5 mg ().
TABLE 2. Analyses of IndexEIB at dierent time points
Contrast Est. 95% CI P-value Est. 95% CI P-value
15 min 4 h
Placebo 18?4 14?5 22?3 15?7 12?4 19?1
Formoterol 4?5 mg 5?40 1?46 9?35 5?19 1?80 8?58
Formoterol 9 mg 2?50 71?43 6?44 3?02 70?36 6?40
Terbutaline 0?5 mg 3?34 70?60 7?28 11?6 8?26 15?0
Placebo-formoterol 9 mg 15?9 10?3 21?5 50?001 12?7 7?96 17?5 50?001
Placebo-formoterol 4?5 mg 13?0 7?41 18?6 50?001 10?6 5?77 15?4 50?001
Placebo-terbutaline 0?5 mg 15?0 9?48 20?6 50?001 4?11 70?67 8?89 0?09
Terbutaline 0?5 mg-formoterol 9 mg 0?84 74?73 6?41 0?76 8?63 3?85 13?4 50?001
Terbutaline 0?5 mg-formoterol 4?5 mg 72?06 77?65 3?53 0?46 6?46 1?66 11?3 0?009
Formoterol 4?5 mg-formoterol 9 mg 2?90 72?67 8?47 0?30 2?17 72?62 6?96 0?37
8 h 12 h
Placebo 15?6 12?2 19?1 16?5 13?2 19?8
Formoterol 4?5 mg 8?19 4?75 11?6 9?29 6?01 12?6
Formoterol 9 mg 5?04 1?62 8?46 5?43 2?15 8?70
Terbutaline 0?5 mg 14?4 11?0 17?8 19?1 15?8 22?3
Placebo-formoterol 9 mg 10?6 5?77 15?4 50?001 11?1 6?47 15?7 50?001
Placebo-formoterol 4?5 mg 7?46 2?61 12?3 0?003 7?24 2?59 11?9 50?001
Placebo-terbutaline 0?5 mg 1?23 73?61 6?07 0?61 72?54 77?18 2?09 0?28
Terbutaline 0?5 mg-formoterol 9 mg 9?38 4?53 14?2 50?001 13?6 9?01 18?3 50?001
Terbutaline 0?5 mg-formoterol 4?5 mg 6?23 1?37 11?1 0?01 9?78 5?13 14?4 50?001
Formoterol 4?5 mg-formoterol 9 mg 3?15 71?70 8?00 0?20 3?87 70?77 8?50 0?10
PROTECTION BY FORMOTEROL VIA TURBUHALER1 AGAINST EIB 665exacerbation associated with exercise and other stimuli,
which trigger bronchoconstriction. The present results
demonstrate that long-acting formoterol Turbuhaler is a
superior alternative to short-acting terbutaline in protectionagainst bronchoconstriction induced by a repeated exercise
during a period of 12 h. The technique of repeated exercise
test after a single dose reflects the daily life situation for
many children, which includes scheduled physical activities
FIG. 5. IndexEIB at dierent time points after drug administration divided by age group. (a) IndexEIB, younger age group
(6–12 years); (b) IndexEIB, older age group (13–17 years). Placebo (*), formoterol 4?5 mg (&), formoterol 9 mg (D),
terbutaline 0?5 mg ().
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activities, during the day. A practical implication of the
present results is that the children need only to take one
single dose in the morning and may then feel confident to
take part in physical activities without needing to carry any
rescue inhaler or to think about timing an extra inhalation
before exercise. The children will not feel dierent from
other children, which should have positive impact on their
self confidence and quality of life (12–14).
The fall in FEV1 during the randomized placebo day was
smaller than the mean fall seen at the screening day (18%
compared with 32%), indicating a placebo eect. A similar
eect on EIB has been reported before (26,27). Both
formoterol and terbutaline had a limited bronchodilating
eect, 7 and 6% after 4?5 and 9 mg formoterol respectively
and 5% after terbutaline. This is what would be expected in
patients with relatively high baseline FEV1 (74–106% of
predicted normal value). A reversibility test was not
performed in these patients; the main inclusion criterion
was a fall in FEV1 after exercise. A high baseline FEV1 was
chosen as a safety measure to avoid very low post-exercise
FEV1 and to eliminate the contribution of bronchodilating
eect to the protection against EIB.
In contrast to the long acting b2-agonists, the short-
acting drugs have demonstrated shorter duration of
bronchoprotective eect against exercise than that of the
bronchodilatory eect (25). This was also applicable in the
present study. Both formoterol and terbutaline gave
statistically significant protection relative to placebo against
bronchoconstriction induced by exercise performed at 15
min after drug administration. The protection of formoter-
ol lasted for 12 h, while that of terbutaline was the same as
after placebo during exercise performed 4 h after admin-
istration. Prolonged bronchoprotection of formoterol dur-
ing exercise was also shown in adults on regular treatment
with formoterol Turbuhaler 9 mg b.i.d. A statistically
significant protection against EIB for up to 12 h was
shown after a mean treatment period of 16 days (range 8–44
days). Although the protection was somewhat lower at the12-h ECT compared to what was seen earlier in the day,
formoterol had about three times longer duration of eect
than the short-acting bronchodilators normally used for the
prevention of EIB (22). A prolonged protective eect of
long-acting b2-agonists against bronchoconstriction in-
duced by other stimuli has been reported in previous
investigations (28–30).
Despite the fact that a majority of the patients were on
regular use of inhaled GCSs, they all showed a fall in FEV1
after exercise. In these patients, a single dose of formoterol
4?5 or 9 mg was seen to give the protection they needed
against EIB.
In conclusion formoterol was shown to be a better
alternative to terbutaline against bronchoconstriction
induced by repeated exercise challenge for up to 12 h in
children.
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